In ALL, it is expressed in almost 100% of newly diagnosed cases, making CD19 an ideal target for CAR-T cell therapy due to both its almost universal expression in ALL and its restriction to normal B lymphocytes which are “dispensable” cells. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.